Upregulation of SLC35A2 facilitates malignant progression and autophagy in lung adenocarcinoma
Science Progress · 2026-10 · 109 (4)
DOI: 10.1177/00368504261506367 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Progress, online erschienen am 11.11.2026. Verfasst von Yidan Xu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China. Hauptthemen laut MEDLINE: Autophagy, Adenocarcinoma of Lung, Lung Neoplasms, Up-Regulation. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Scientific Research Project of Higher Education Institutions in Anhui Province.
Abstract (Originalsprache)
Objective
Solute carrier family 35 member A2 (SLC35A2), a glycosylation-associated transporter, has been implicated in the progression of several malignancies, but its role in lung adenocarcinoma (LUAD) remains unclear. This study aimed to investigate the clinical significance and biological function of SLC35A2 in LUAD.
Methods
This retrospective cohort study included 80 patients with histologically confirmed LUAD. SLC35A2 expression and its association with clinicopathological characteristics and survival were evaluated. Gain- and loss-of-function experiments assessed LUAD cell proliferation, migration, and invasion, and a nude mouse xenograft model evaluated tumor growth in vivo. Autophagy-related proteins, tandem fluorescent LC3 puncta, and the effects of chloroquine treatment were examined. A prognostic model incorporating independent prognostic factors was internally validated using 1,000 bootstrap resamples.
Results
SLC35A2 was upregulated in LUAD tissues and associated with adverse clinicopathological features and poor overall survival. Multivariate Cox analysis identified SLC35A2 as an independent prognostic factor. The model had an apparent C-index of 0.714 and an optimism-corrected C-index of 0.684. SLC35A2 overexpression enhanced LUAD cell proliferation, migration, invasion, and xenograft growth, whereas its depletion produced the opposite effects. Overexpression was associated with a higher LC3-II/LC3-I ratio, increased Beclin1, reduced p62, and more yellow LC3 puncta per cell; the difference in red-only puncta was not statistically significant. Chloroquine reduced CCK-8 signals in SLC35A2-overexpressing cells.
Conclusions
SLC35A2 promotes malignant phenotypes in LUAD and is associated with autophagy-related changes. These findings support its potential as a prognostic biomarker and candidate therapeutic target, while the contribution of autophagy to its tumor-promoting effects requires further mechanistic validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.
ORCID-Profile: Yidan Xu
Förderung
- The Scientific Research Project of Higher Education Institutions in Anhui Province
Zitieren
APA
Xu, Y., Sun, X., Chen, Z., & Hao, J. (2026). Upregulation of SLC35A2 facilitates malignant progression and autophagy in lung adenocarcinoma. Science Progress, 109(4). https://doi.org/10.1177/00368504261506367
Vancouver
Xu Y, Sun X, Chen Z, Hao J. Upregulation of SLC35A2 facilitates malignant progression and autophagy in lung adenocarcinoma. Science Progress. 2026;109(4). doi:10.1177/00368504261506367
BibTeX
@article{Xu2026,
author = {Xu, Yidan and Sun, Xiaonan and Chen, Zhiyang and Hao, Jiqing},
title = {Upregulation of SLC35A2 facilitates malignant progression and autophagy in lung adenocarcinoma},
journal = {Science Progress},
year = {2026},
volume = {109},
number = {4},
doi = {10.1177/00368504261506367}
}
EUVIMED